Yanagië H, Tomita T, Kobayashi H, Fujii Y, Takahashi T, Hasumi K, Nariuchi H, Sekiguchi M
Department of Clinical Oncology, University of Tokyo, Japan.
Br J Cancer. 1991 Apr;63(4):522-6. doi: 10.1038/bjc.1991.124.
An immunoliposome containing a 10B-compound has been examined as a selective drug delivery system in boron neutron-capture therapy. Liposomes, conjugated with monoclonal antibodies specific for carcinoembryonic antigen (CEA) were shown to bind selectively to cells bearing CEA on their surface. The immunoliposomes attached to tumour cells suppressed growth in vitro upon thermal neutron irradiation and suppression was dependent upon the concentration of the 10B-compound in the liposomes and on the density of antibody conjugated to the liposomes. The results suggest that immunoliposomes containing the 10B-compound could act as a selective and efficient carrier of 10B atoms to target tumour cells in boron neutron-capture therapy.
一种含有硼-10化合物的免疫脂质体已作为硼中子俘获治疗中的一种选择性药物递送系统进行了研究。与癌胚抗原（CEA）特异性单克隆抗体偶联的脂质体显示能选择性地结合表面带有CEA的细胞。附着于肿瘤细胞的免疫脂质体在热中子照射后能抑制体外生长，且抑制作用取决于脂质体中硼-10化合物的浓度以及与脂质体偶联的抗体密度。结果表明，含有硼-10化合物的免疫脂质体可作为硼中子俘获治疗中硼-10原子靶向肿瘤细胞的选择性高效载体。
